Home >> Tag Archives: AstraZeneca—

Tag Archives: AstraZeneca—

FDA OKs Imfinzi for unresectable stage III NSCLC

March 13, 2018—AstraZeneca and MedImmune, its biologics research and development arm, announced the FDA has approved Imfinzi (durvalumab) for the treatment of patients with unresectable stage III non-small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. “This is the first treatment approved for stage III unresectable non-small cell lung cancer to reduce the ...

Read More »